
Roche’s Tecentriq/Cotellic combo therapy fails to impress in colorectal cancer
pharmafile | May 11, 2018 | News story | Medical Communications, Research and Development | Cancer, Cotellic, Roche, pharma, tecentriq
Roche has been rocked by a Phase 3 weak showing from its combination Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer (CRC), which failed to meet its primary endpoint in patient’s whose disease progressed or who proved intolerant to at least two systemic chemotherapy regimens.
The combo did not live up to expectations, failing to improve overall survival (OS) compared to regorafenib (Bayer’s Stivarga). Over 95% of the 363 participants enrolled in the trial have microsatellite stable (MSS) tumours, which, according to available data, have not proved clinically responsive to checkpoint inhibitors as monotherapy. This was reinforced in the results of the trial, where the Tecentriq-alone group did not see clinically-meaningful results.
The safety profile of the drug pair remained consistent with previous findings.
“While these results are not what we hoped for, we remain committed to applying our deep experience to develop medicines that will improve outcomes for people living with gastrointestinal cancers,” said Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “In particular, we have a number of studies evaluating medicines in colorectal cancer that could play an important role in the treatment of people with this disease in the future.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …






